A Friday Satellite Symposium Preceding the 54th ASH Annual Meeting
Friday, December 7, 2012
6:00 pm – 8:00 pm
Omni Hotel at CNN Center
International Ballroom E-F
Atlanta, Georgia
Program Overview
Join us for a timely and engaging expert led discussion regarding the newest evidence-based approaches for the management of patients with chronic myelogenous leukemia (CML) throughout the life cycle of the disease. The roundtable discussions will focus on appropriate monitoring and testing, selection and tailoring of treatment, as well as addressing barriers through the integration of new and emerging therapeutics into the existing treatment paradigm for CML.
Target Audience
This activity is designed for practicing physicians, nurse practitioners, nurses, and physician assistants who have an interest in enhancing their clinical skills in the treatment of patients with CML.
Learning Objectives
Upon completion of this educational activity, participants should be able to:
- Compare and contrast TKI therapy options in the front line setting based on clinical trial evidence including efficacy and safety with considerations for trial limitations
- Select appropriate TKI therapy for newly diagnosed, treatment-naïve, chronic-phase CML patients according to patient-specific risk factors
- Relate causes of primary and secondary resistance, appropriate testing and monitoring when they occur, and interventions to overcome them
- Recall clinical findings related to efficacy and safety, as well as trial limitations for agents undergoing investigation for overcoming the T315I mutation, their mechanisms of action, and the importance of clinical trial referral for such patients
- Select appropriate treatments for progressive disease, accelerated phase and blast crisis CML based on each patient’s historical response, adverse event tolerance level, risk factors, and the recognition of the appropriate setting for AHSCT
- Demonstrate appropriate CML patient management throughout all phases of CML including current practice guideline recommendations for treatment response monitoring, tailoring of therapy, supportive care, TKI side-effect management, and strategies to ensure adherence to therapy
Agenda
Dinner will be served from 5:15 pm – 6:00 pm before the symposium in International Ballroom A-D
| 6:00 pm – 6:15 pm | Welcome and Introductions Joseph Jurcic, MD |
| 6:15 pm – 6:45 pm | Case-Based Roundtable Discussions Newly Diagnosed CML – Addressing Primary Resistance Discussion Leader: Javier Pinilla-Ibarz, MD, PhD Newly Diagnosed Chronic Phase CML – Challenges of Identifying Non-Adherence to Therapy Discussion Leader: Thomas G. Martin III, MD Strategies in the Management of Secondary Resistance and in Chronic Phase CML Discussion Leader: Mark L. Heaney, MD, PhD |
| 6:45 pm – 6:55 pm | Question and Answer Session Audience participation |
| 6:55 pm – 7:15 pm | Case-Based Roundtable Discussions Management of the Accelerated Phase CML Patient Discussion Leader: Javier Pinilla-Ibarz, MD, PhD Management of the Blast Crisis CML Patient Discussion Leader: Mark L. Heaney, MD, PhD |
| 7:15 pm – 7:25 pm | Question and Answer Session Audience participation |
| 7:25 pm – 7:35 pm | Addressing Clinical Barriers to Overcoming Resistance, Treatment Failure - Emerging Therapeutics Joseph Jurcic, MD |
| 7:35 pm – 7:50 pm | Faculty Panel Roundtable Discussion |
| 7:50 pm – 8:00 pm | Closing Remarks and Adjournment Joseph Jurcic, MD |
Faculty
Joseph Jurcic, MD – Moderator
Leukemia Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York
Mark L. Heaney, MD, PhD
Associate Attending Physician
Memorial Sloan-Kettering Cancer Center
New York, New York
Thomas G. Martin III, MD
Clinical Professor of Medicine
Adult Leukemia and Bone Marrow Transplantation Program
University of California, San Francisco
San Francisco, California
Javier Pinilla-Ibarz, MD, PhD
Assistant Member
Malignant Hematology and Immunology Program
H. Lee Moffitt Cancer Center
Tampa, Florida
Accreditation
CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSING CREDIT
Accreditation Statement: MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 2.0 contact hours. Program Number: 12-322-287
For information on applicability and acceptance of continuing nursing education credit for this activity, please consult your professional licensing board.
Disclosure
As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Americans with Disabilities Act/Special Needs
MediCom Worldwide, Inc. is committed to equality of educational opportunity and does not discriminate against applicants, students, or employees on the basis of race, color, religion, sex, national origin, age, disability, veterans status, or sexual orientation. If you require reasonable accommodations for a disability in order to participate fully in this continuing education activity, please call 800-408-4242 no later than 14 days prior to the activity.
Instructions for Participation and Credit
There are no fees for participating in this activity. All participants must complete the Activity Evaluation Form. Participants must receive a minimum score of 70% on the self-assessment portion of the form to qualify for CE credit. Certificates will be mailed 4 to 6 weeks following receipt of a completed, qualified form.
Hardware/Software/Internet Requirements
MediCom Worldwide, Inc. requires Internet Explorer® version 7.0 or higher, or Firefox 3.0 or higher, a computer running Windows® XP, Windows® Vista, Windows® 7, or Mac OS X, 512MB of RAM or greater, 1.5 GHZ or faster processor, and a screen resolution of 1024x768 or higher. Certain educational activities may require additional software to view. These activities will be marked with the information and/or links to the required software. That software may be Adobe® Flash® Player, Adobe® Acrobat®, Windows Media® Player or Microsoft® Silverlight™.
 |
Supported by an educational grant from Teva Pharmaceuticals |
©2012 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067. 1-800-408-4242
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.